Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Elekta ABEKTAY -0.19%72 EV-to-EBITDA is 17.89 as of Aug. 17, 2026, which is 20% above its 10-year median of 14.89. GuruFocus rates EKTAY with a GF Score™ of 72/100 and a GF Value™ of $6.48 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 513 Medical Devices & Instruments companies, Elekta AB ranks worse than 60.23% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Elekta AB's enterprise value is $2,570 Mil.
Elekta AB's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 was $144 Mil. Therefore, Elekta AB's EV-to-EBITDA for today is 17.89.
The historical rank and industry rank for Elekta AB's EV-to-EBITDA or its related term are showing as below:
EKTAY'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.89 Med: 14.89 Max: 37.22
Current: 17.89
During the past 13 years, the highest EV-to-EBITDA of Elekta AB was 37.22. The lowest was 7.89. And the median was 14.89.
EKTAY's EV-to-EBITDA is ranked worse than 60.23% of 513
companies
in the Medical Devices & Instruments industry
Industry Median: 14.95
vs EKTAY: 17.89
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Elekta AB's share price for today is $5.57.
Elekta AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.149.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Elekta AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Elekta AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elekta AB EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Elekta AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Elekta AB's EV-to-EBITDA falls into.
Elekta AB's current Enterprise Value is $2,570 Mil.
Elekta AB's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $144 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elekta AB (EKTAY) has a EV-to-EBITDA of 17.89 as of Aug. 17, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Elekta AB. This is 20% above median its historical median of 14.89. Over the past decade, Elekta AB's EV-to-EBITDA has ranged from 7.89 to 37.22. According to the industry distribution chart, Elekta AB ranks #309 out of 513 companies in the Medical Devices & Instruments industry, placing it in the top 60.2%.
Is Elekta AB's EV-to-EBITDA too high?
Elekta AB's current EV-to-EBITDA of 17.89 is 20% above median its 10-year median of 14.89. Over the past 10 years, this metric has ranged from a low of 7.89 to a high of 37.22. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.95. Elekta AB's value of 17.89 is 19.7% above this industry median. Based on the distribution chart, Elekta AB ranks #309 out of 513 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Elekta AB has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Elekta AB's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Elekta AB ranks #309 out of 513 companies for EV-to-EBITDA. This places Elekta AB in the lower half of its industry. The industry median EV-to-EBITDA is 14.95. Elekta AB's value of 17.89 is 19.7% above this benchmark. Historically, Elekta AB's own EV-to-EBITDA has ranged from 7.89 to 37.22 over the past decade. While the company's 10-year median is 14.89 vs. the industry median of 14.95, Elekta AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.95, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Elekta AB's current EV-to-EBITDA of 17.89 is 19.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Elekta AB. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elekta AB's current EV-to-EBITDA is 17.89, which is 20% above median its own 10-year median of 14.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elekta AB stock overvalued right now?
Based on GuruFocus' analysis, Elekta AB (EKTAY) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.48, compared to a current price of $5.57 — trading 14% below its estimated fair value. The current EV-to-EBITDA is 17.89, which is 20% above median its 10-year median of 14.89 and 19.7% above the Medical Devices & Instruments industry median of 14.95. Elekta AB's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Elekta AB (EKTAY), the current EV-to-EBITDA is 17.89 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elekta AB (EKTAY) Overvalued in 2026?
Based on GuruFocus' analysis, Elekta AB stock appears to be undervalued.
The current stock price of $5.57 is trading 14% below its estimated GF Value™ of $6.48.
GuruFocus considers Elekta AB to be Modestly Undervalued.
Key valuation signals for EKTAY:
EV-to-EBITDA: 17.89 (20% above median its 10-year median of 14.89)
GF Value™: $6.48 vs. price of $5.57 (14% below fair value)
Industry Position: 19.7% above the Medical Devices & Instruments median (#309 of 513)
No single metric tells the full story. See the EKTAY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sweden-based Elekta develops, manufactures, and distributes treatment planning systems for neurosurgery and radiotherapy, including stereotactic radiosurgery and brachytherapy. The company has an installed base of more than 7,300 linear accelerators, Gamma Knife and Unity platforms, as well as brachytherapy installations. The company's sales are evenly distributed across geographies, with North and South America accounting for 29%; Europe, the Middle East, and Africa accounting for 37%; and the Asia-Pacific contributing the remainder.
72GF Score
Get the complete analysis for EKTAY
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EKTAY has been successfully added to your 
